Johnson & Johnson (NYSE:JNJ) Holdings Lowered by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 208,373 shares of the company's stock after selling 4,799 shares during the quarter. Johnson & Johnson accounts for approximately 3.7% of Levin Capital Strategies L.P.'s holdings, making the stock its 4th biggest holding. Levin Capital Strategies L.P.'s holdings in Johnson & Johnson were worth $34,557,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC grew its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in Johnson & Johnson by 114.9% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 3,660 shares of the company's stock valued at $529,000 after acquiring an additional 1,957 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE boosted its holdings in Johnson & Johnson by 24.7% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 863 shares of the company's stock valued at $125,000 after acquiring an additional 171 shares in the last quarter. Finally, Sierra Summit Advisors LLC boosted its holdings in Johnson & Johnson by 23.9% in the fourth quarter. Sierra Summit Advisors LLC now owns 13,927 shares of the company's stock valued at $2,014,000 after acquiring an additional 2,682 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 2.2%

Shares of JNJ opened at $171.08 on Tuesday. The stock has a market capitalization of $412.02 billion, a price-to-earnings ratio of 18.30, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $171.19. The business's 50 day simple moving average is $157.82 and its 200-day simple moving average is $156.91. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the firm earned $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. Raymond James Financial cut their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Guggenheim restated a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.